A phase I and pharmacokinetic study of intraperitoneal topotecan.

Hofstra, L S; Bos, A M; de Vries, E G; van der Zee, A G; Beijnen, J H; Rosing, H; Mulder, N H; Aalders, J G; Willemse, P H

Hofstra, L S; Bos, A M; de Vries, E G; van der Zee, A G; Beijnen, J H; Rosing, H; Mulder, N H; Aalders, J G; Willemse, P H.

Affiliation

Hofstra LS; Department of Medical, Gynaecologic Oncology, University Hospital Groningen, PO Box 30.001, Groningen, RB, 9700, The Netherlands.

Br J Cancer ; 85(11): 1627-33, 2001 Nov 30.

Article in En | MEDLINE | ID: mdl-11742479

Subject(s)

Antineoplastic Agents/pharmacokinetics; Ovarian Neoplasms/drug therapy; Topotecan/pharmacokinetics; Adult; Aged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Area Under Curve; Dose-Response Relationship, Drug; Exanthema/chemically induced; Fatigue/chemically induced; Female; Humans; Injections, Intraperitoneal; Metabolic Clearance Rate; Middle Aged; Nausea/chemically induced; Ovarian Neoplasms/metabolism; Topotecan/adverse effects; Topotecan/therapeutic use; Treatment Outcome; Vomiting/chemically induced

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Topotecan / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2001 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google